| Drug Name | Valtense Plus (Hydrochlorothiazide, Valsartan) |
|---|---|
| Drug Class |
Anti-hypertension
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Cardiology
|
| Risk |
restriction of combined use of medicines affecting the renin-angiotensin aldosterone system (RAAS) for medicinal products containing Valsartan- angiotensin-receptor blocker |
| Dear Healthcare provider letter DHPC |
|